14 hasil untuk "David Nemirovsky"
Menampilkan 1–14 · 0,03 detik · RSS
-
Artikel Jurnal
Virtual Biostats Day: An Interactive Online Biostatistics Outreach Program Directed at High School Students in Groups Historically Underrepresented in STEM Careers
Persistent underrepresentation of Black and Hispanic Statistics degree holders relative to the U.S. population occurs at all levels in post-secondary education, contributing to the underrepresentation of Black and Hispanic Bio/Statisticians. Attempting to address this inequity before the…
-
Artikel Jurnal
Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction
Abstract: The utility of a midcycle bone marrow biopsy (BMB) for early assessment of response in patients with acute myeloid leukemia (AML) after intensive chemotherapy (IC) induction is contested. Even when challenged, there is little consideration as to the possibility of different response…
-
Artikel Jurnal
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly…
-
Artikel Jurnal
Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model
Abstract Smoldering multiple myeloma (SMM) is a heterogeneous precursor with variable risk of progression to multiple myeloma (MM). Current risk models rely on baseline features, limiting predictive accuracy. We aimed to define evolving risk factors and integrate them with the 2/20/20 model to…
-
Artikel Jurnal
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Abstract While CAR T has shown superior efficacy in earlier line of therapy [1, 2] for functionally high-risk multiple myeloma (FHRMM), outcomes with its use in later lines (3+) for FHR disease remain unknown. We describe a single-center experience of FHRMM patients (pts), defined as those with…
-
Artikel Jurnal
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
Abstract: Patients with relapsed/refractory (R/R) multiple myeloma (MM) are often frail with preexisting comorbidities and poor performance status (PS). To evaluate clinical characteristics and outcomes based on frailty, we conducted a single-center retrospective study of patients with R/R MM who…
-
Artikel Jurnal
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy…
-
Artikel Jurnal
Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma
Abstract Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T‐cell therapy, and yet, their dose‐specific impact on outcomes remains uncertain. We retrospectively…
-
Artikel Jurnal
Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL
Abstract: The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) receiving asparaginase-based induction is high despite primary thromboprophylaxis. Our aim was to derive and externally validate a VTE risk prediction model in patients with ALL receiving…